Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma
The purpose of the study is to evaluate the safety and effectiveness of melphalan for injection for autologous stem cell transplant in multiple myeloma
Multiple Myeloma
DRUG: Melphalan
1 year Progression Free Survival, Plan to enroll all trial subjects within 8 months and follow up 1 year for each subject after enrollment, 20 months
The purpose of the study is to evaluate the safety and effectiveness of melphalan for injection for autologous stem cell transplant in multiple myeloma